Genentech Could Regain the Blindness-Related Disease Market with New Treatment

After announcing topline data from two identical Phase III trials, Roche’s Genentech has doubled down on data and is now showing positive results from four studies for its newest blindness-fighting treatment.

Faricimab is an injectable treatment to maintain the vision of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). These are two of the leading causes of blindness with nAMD responsible for 90% of all blindness resulting from AMD.